Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech presents data from two Phase II trials

DNA reported data from a 99-patient, open-label study of its recombinant humanized monoclonal antibody against vascular endothelial growth factor (rhuMAb-VEGF) with carboplatin/paclitaxel to treat non-small cell lung cancer.

Read the full 283 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE